A more complete understanding of these aspects of osteocyte biology may help to design novel treatments for the mineralization defects observed in diseases associated with excessive osteocytic Fgf23 secretion such as XLH or chronic kidney disease. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.